What happened with IRD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Opus Genetics is a clinical-stage biotechnology company focused on gene therapies for inherited retinal diseases. These treatments remain in development; its only approved product is RYZUMVI, an eye drop that reverses pupil dilation caused by medicines used during eye examinations.
Viatris sells RYZUMVI and holds exclusive rights to develop and commercialize the underlying phentolamine ophthalmic solution for specified uses across most of the world. Opus retains rights in certain excluded Asian markets. Viatris reimburses agreed development costs, pays royalties on sales and may make further payments when regulatory or sales milestones are reached. Current revenue under this partnership comes mainly from ongoing development work, with royalties contributing much less.
Opus therefore relies heavily on Viatris to turn its approved eye drops into sales. Its gene therapies and additional uses of the eye drops, including presbyopia, still need regulatory approval before they can be marketed. Continuing its pipeline development also requires additional funding.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Opus Genetics’ future RYZUMVI royalties also depend on defending its patents against Sandoz’s proposed generic, while Tenpoint Therapeutics adds direct competition in presbyopia.
Viatris turns Opus Genetics’ PS eye drops into revenue by licensing and selling them and paying Opus development reimbursements, milestones and sales royalties. Watch RYZUMVI sales and the FDA’s October 17, 2026 decision on PS for presbyopia, but note that Opus’s 2025 revenue from Viatris came mainly from R&D services, not royalties.
LENZ Therapeutics sells VIZZ eye drops to treat presbyopia, competing directly for patients with Opus Genetics’ proposed PS presbyopia treatment. Watch VIZZ’s uptake following its broad retail-pharmacy availability in November 2025 as a measure of the competition awaiting PS.
MeiraGTx competes with Opus Genetics in developing a gene therapy for patients with RDH12-related inherited retinal disease; both use AAV to deliver gene therapies into the eye. Its RDH12 trial progress is the clearest comparison to watch for Opus’s program.
AbbVie’s VUITY eye drops compete for presbyopia patients with Opus Genetics’ PS treatment being developed with Viatris, which would sell it and pay Opus royalties. VUITY’s position in this patient group matters more to that rivalry than AbbVie’s overall drug sales.
REGENXBIO’s retinal gene-therapy progress is relevant to Opus Genetics because both develop treatments that use AAV to carry genes into the eye, though Opus focuses on inherited retinal diseases. Watch results from REGENXBIO’s sura-vec for wet AMD and diabetic retinopathy for evidence on the safety and durability of this approach.
LENZ Therapeutics, Inc. earningsLENZ
LENZ Therapeutics’ report will show how patients are taking up VIZZ for presbyopia, a measure of the competition facing Opus Genetics’ PS if Viatris sells it.
Look for continued growth in VIZZ sales or use, alongside what LENZ says about its retail-pharmacy distribution. Rising use would show that prescription drops are drawing presbyopia patients, but also that PS would face a rival with an established patient base. Weak use would leave PS more room, while showing that demand for this kind of treatment remains unproven.
REGENXBIO Inc. earningsRGNX
REGENXBIO’s report will show what its eye-directed AAV gene therapy reveals about safety and durability, risks Opus Genetics also faces in inherited-retinal-disease programs.
Watch sura-vec’s safety and how long its effects last in wet AMD and diabetic retinopathy. Manageable safety and durable effects would ease one key uncertainty for eye-directed AAV therapies, including Opus’s programs; safety problems or waning effects would underscore how immune responses or limited durability could hinder them. The companies target different diseases, so these results are not direct evidence of Opus’s efficacy.
Viatris Inc. earningsVTRS
Viatris’ report will show how it is advancing PS and selling its eye products, offering clues about the partner responsible for Opus Genetics’ development reimbursements and potential product-based payments.
Separate Viatris’s comments on PS development from commercialization of eye products such as RYZUMVI. Continued PS work would show the collaboration is advancing, but Opus currently earns mainly for research services; sales-linked milestones and royalties depend on licensed products being sold. Delays or weak commercialization would make the transition from reimbursements to sales-based income harder. RYZUMVI sales do not directly establish demand for PS.
Opus Genetics, Inc. earningsThis company
Opus Genetics’ report will show whether revenue for research work funded by Viatris is keeping pace with its spending on inherited-retinal-disease programs.
Read revenue from research services under the Viatris agreement alongside cash used in operations. Rising service revenue with controlled cash use would show that the collaboration is helping support Opus’s pipeline shift; falling revenue or faster cash use would show internal development spending outpacing that support. This revenue mainly reflects completed research work, not product sales or royalties.
